RecruitingPhase 2NCT03971045

Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer

Studying Cerebrotendinous xanthomatosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
European Institute of Oncology
Intervention
Pembrolizumab(drug)
Enrollment
46 target
Eligibility
18 years · All sexes
Timeline
20202025

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03971045 on ClinicalTrials.gov

Other trials for Cerebrotendinous xanthomatosis

Additional recruiting or active studies for the same condition.

See all trials for Cerebrotendinous xanthomatosis

← Back to all trials